Scientists track Long-Term safety of One-Time gene fix for rare disorder

NCT ID NCT03636438

Summary

This study is tracking the long-term safety and effectiveness of a one-time gene therapy for adults with late-onset OTC deficiency, a rare genetic disorder that affects the body's ability to process protein. It follows 11 adults who previously received the experimental treatment in an earlier trial. The main goal is to monitor for any side effects over a long period and see if the treatment continues to help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Hopital Femme Mere Enfant

    Bron, Rhone, 69677, France

  • Hospital Clinico Universitario de Santiago

    Santiago de Compostela, Coruna, 15706, Spain

  • Hospital Universitario de Cruces. Servicio de Pediatria

    Barakaldo, Vizcaya, 48903, Spain

  • Icahn School of Medicine

    New York, New York, 10029, United States

  • M.A.G.I.C. Clinic

    Calgary, Alberta, T2E 7Z4, Canada

  • Queen Elizabeth Hospital, Department of Endocrinology

    Birmingham, B15 2TH, United Kingdom

  • The Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

  • University Hospital Cleveland Medical Center/Case Western Reserve University

    Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.